>
Sernova logo

SVA - Sernova Share Price

C$1.53 -0.0  -1.9%

Last Trade - 14/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £232.1m
Enterprise Value £226.8m
Revenue £n/a
Position in Universe 471st / 2712
Bullish
Bearish
Unlock SVA Revenue
Momentum
Relative Strength (%)
1m +20.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -46.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Oct 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 January 2021, SernovaCorp. revenues was not reported. Net loss increased 10% toC$1.5M. Higher net loss reflects Research and Dev -Balancing increase from C$36K to C$361K (expense), Othercosts increase of 53% to C$74K (expense), Foreign exchange(gain) loss decrease from C$3K (income) to C$13K (expense).Basic Earnings per Share excluding Extraordinary Itemsremained flat at -C$0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SVA Revenue Unlock SVA Revenue

Net Income

SVA Net Income Unlock SVA Revenue

Normalised EPS

SVA Normalised EPS Unlock SVA Revenue

PE Ratio Range

SVA PE Ratio Range Unlock SVA Revenue

Dividend Yield Range

SVA Dividend Yield Range Unlock SVA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SVA EPS Forecasts Unlock SVA Revenue
Profile Summary

Sernova Corp. is a development-stage regenerative medicine company. The Company is engaged in the development of its Cell Pouch and associated technologies, including therapeutic cells for the treatment of chronic diseases and local immune protection technologies. It is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells placed into its implanted and prevascularized medical device, protected from immune system attack. The Cell Pouch is designed to create a microvessel rich, tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the treatment of chronic diseases, such as diabetes and thyroid disease. Its lead program is the clinical development of the Cell Pouch for treatment of patients with insulin dependent diabetes. It is also evaluating Cell Pouch for the treatment of patients with hemophilia A.

Directors
Last Annual October 31st, 2020
Last Interim January 31st, 2021
Incorporated November 1, 2001
Public Since April 15, 1999
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange TSX Venture Exchange
Shares in Issue 257,924,477
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SVA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SVA
Upcoming Events for SVA
Frequently Asked Questions for Sernova
What is the Sernova share price?

As of 14/04/21, shares in Sernova are trading at C$1.53, giving the company a market capitalisation of £232.1m. This share price information is delayed by 15 minutes.

How has the Sernova share price performed this year?

Shares in Sernova are currently trading at C$1.53 and the price has moved by 1.06k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sernova price has moved by 0.758k% over the past year.

What are the analyst and broker recommendations for Sernova?

Of the analysts with advisory recommendations for Sernova, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sernova is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Sernova next release its financial results?

Sernova is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-01-31
What is the Sernova dividend yield?

Sernova does not currently pay a dividend.

Does Sernova pay a dividend?

Sernova does not currently pay a dividend.

When does Sernova next pay dividends?

Sernova does not currently pay a dividend.

How do I buy Sernova shares?

To buy shares in Sernova you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sernova?

Shares in Sernova are currently trading at C$1.53, giving the company a market capitalisation of £232.1m.

Where are Sernova shares listed? Where are Sernova shares listed?

Here are the trading details for Sernova:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: SVA
What kind of share is Sernova?

Based on an overall assessment of its quality, value and momentum, Sernova is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sernova share price forecast 2021?

Shares in Sernova are currently priced at C$1.53. At that level they are trading at 61.29% discount to the analyst consensus target price of 0.00.

How can I tell whether the Sernova share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sernova. Over the past six months, the relative strength of its shares against the market has been 0.338k%. At the current price of C$1.53, shares in Sernova are trading at 0.121k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sernova PE Ratio?

We were not able to find PE ratio data for Sernova.

Who are the key directors of Sernova?

Sernova's management team is headed by:

Jeffrey Bacha - IND
Philip Toleikis - PRE
James Parsons - IND
Frank Holler - NEC
David Swetlow - CFO
Deborah Brown - IND
Who are the major shareholders of Sernova?

Here are the top five shareholders of Sernova based on the size of their shareholding:

Toleikis (Philip) Individual Investor
Percentage owned: 2.03% (5.23m shares)
Bacha (Jeffrey ) Individual Investor
Percentage owned: 0.22% (578k shares)
Holler (Frank A) Individual Investor
Percentage owned: 0.1% (250k shares)
Parsons, James Todd Individual Investor
Percentage owned: 0.08% (215k shares)
StoneCastle Investment Management Inc. Investment Advisor
Percentage owned: 0.07% (173k shares)
Similar to SVA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.